Contrasting Nicox (OTCMKTS:NICXF) and A.P. Møller – Mærsk A/S (OTCMKTS:AMKBY)

Nicox (OTCMKTS:NICXF) and A.P. Møller – Mærsk A/S (OTCMKTS:AMKBY) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Nicox and A.P. Møller – Mærsk A/S, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nicox	0	0	0	0	N/A
A.P. Møller – Mærsk A/S	5	4	3	0	1.83

Profitability

This table compares Nicox and A.P. Møller – Mærsk A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nicox	N/A	N/A	N/A
A.P. Møller – Mærsk A/S	7.48%	-0.22%	-0.20%

Risk and Volatility

Nicox has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, A.P. Møller – Mærsk A/S has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.

Valuation & Earnings

This table compares Nicox and A.P. Møller – Mærsk A/S’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nicox	$5.52 million	3.99	-$29.25 million	N/A	N/A
A.P. Møller – Mærsk A/S	$51.07 billion	0.51	$3.82 billion	$1.11	6.29

A.P. Møller – Mærsk A/S has higher revenue and earnings than Nicox.

Summary

A.P. Møller – Mærsk A/S beats Nicox on 5 of the 8 factors compared between the two stocks.

About Nicox

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.

About A.P. Møller – Mærsk A/S

A.P. Møller – Mærsk A/S, together with its subsidiaries, engages in the ocean transport and logistics business in Denmark and internationally. It operates through Ocean, Logistics & Services, Terminals, and Towage & Maritime Services segments. The Ocean segment is involved in container shipping activities, including demurrage and detention, terminal handling, documentation and container services, and container storage, as well as transshipment hubs. The Logistics & Services segment offers integrated transportation solutions; fulfillment and management solutions, such as landside and air transportation; warehousing, distribution, and depot services; and supply chain management, cold chain logistics, and custom brokerage services. The Terminals segment engages in gateway terminal activities. The Towage & Maritime Services segment provides offshore towage and marine services under the Svitzer brand; reefer containers; offshore supply services; trading; and marine services and integrated solutions to the energy sector. It also offers digital solutions that offer booking, managing, tracking of shipments, and other related activities. The company serves fashion and lifestyle, retail, automotive, chemicals, technology, and FMCG industries. A.P. Møller – Mærsk A/S was founded in 1904 and is headquartered in Copenhagen, Denmark.